Medicine details

Medicine name:
olaratumab (Lartruvo)
Indication:
In combination with doxorubicin, for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Date advice published:
13 November 2017